ALK and lung carcinoma: In patients with ALK-positive ALCL, there are efforts to study the use of crizotinib, an oral small-molecule tyrosine kinase inhibitor of ALK, which has been FDA approved for the treatment of lung cancer harboring a translocation in the ALK gene.